<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01832987</url>
  </required_header>
  <id_info>
    <org_study_id>SXT8469</org_study_id>
    <nct_id>NCT01832987</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Parameters of Co-trimoxazole</brief_title>
  <official_title>Pharmacokinetic Parameters of 960 mg Co-trimoxazole Once Daily in Patients With Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:&#xD;
&#xD;
      Treatment of multidrug or extensively drug resistant tuberculosis (MDR/XDR-TB) is a real&#xD;
      challenge as failure in response to treatment and serious side-effects are frequently&#xD;
      encountered. New, more effective drugs with less side effects are therefore urgently needed&#xD;
      to solve this problem. Although several new drugs against TB are in the pipeline, physicians&#xD;
      currently have limited treatment options for treatment of complicated MDR/XDR-TB cases.&#xD;
      Therefore, drugs developed and labeled for other infectious diseases are evaluated for TB.&#xD;
      Co-trimoxazole consists of sulfamethoxazole and trimethoprim. Sulfamethoxazole could be&#xD;
      effective in the treatment of tuberculosis as shown by Forgacs et al. and Huang et al.&#xD;
&#xD;
      Furthermore, with dried blood spot (DBS) analysis, the exposure to co-trimoxazole could be&#xD;
      analyzed with only some blood drops withdrawn with a finger prick on paper. This paper is&#xD;
      suitable for storage, transportation and subsequently analysis without additional cooling or&#xD;
      storage requirements.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      The main objective of this prospective clinical trial is to evaluate pharmacokinetics of 960&#xD;
      mg co-trimoxazole in TB patients. This clinical trial will provide important information on&#xD;
      PK of co-trimoxazole in TB patients for future studies.&#xD;
&#xD;
      The second objective is to calculate the T&gt;MIC and AUC0-24h/Minimal inhibitory concentration&#xD;
      (MIC) ratio as efficacy predicting parameter. Furthermore, the analysis of dried blood spots&#xD;
      will be clinically validated by comparing results of blood samples withdrawn from venous&#xD;
      blood versus withdrawn by finger prick and transferred to filter paper. Retrospectively, data&#xD;
      from this study can be used for limited sampling strategies for co-trimoxazole based on a&#xD;
      pharmacokinetic population model constructed from the full PK curves of the patients.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      A prospective pharmacokinetic study.&#xD;
&#xD;
      Study population: 12 TB patients.&#xD;
&#xD;
      Intervention: on 4 to 6 days, 960 mg co-trimoxazole daily will be added to the normal&#xD;
      treatment regimen.&#xD;
&#xD;
      Main study parameters/endpoints:&#xD;
&#xD;
      The pharmacokinetic parameters (Vd, Cl, AUC, etc) of co-trimoxazole are the primary endpoints&#xD;
      of the study. The T&gt;MIC and AUC0-24h/Minimal inhibitory concentration (MIC) ratio are most&#xD;
      likely the best predictive parameters for efficacy of co-trimoxazole treatment and will be&#xD;
      calculated for a range of M tuberculosis isolates.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>4th, 5th or 6th day</time_frame>
    <description>Measuring the AUC over 24 hours of sulfamethoxazole, one out of two compounds of co-trimoxazole after obtaining steady state (960 mg co-trimoxazole).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of the AUC/MIC and T&gt;MIC</measure>
    <time_frame>4th, 5th or 6th day</time_frame>
    <description>Determination of the area under the curve divided by the mean inhibitory concentration and the time above MIC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Validating DBS analysis</measure>
    <time_frame>4th, 5th or 6th day</time_frame>
    <description>Validating the analysis of dried blood spots for therapeutic drug monitoring by comparing the concentration measured in venous blood with the concentration measured using the dried blood spot method.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Population pharmacokinetic model and limited sampling strategies</measure>
    <time_frame>4th, 5th or 6th day</time_frame>
    <description>Developing a population pharmacokinetic model to predict pharmacokinetic parameters of sulfamethoxazole. With this population pharmacokinetic model, a limited sampling strategy will be developed.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>co-trimoxazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On 4, 5 or 6 consecutive days, 960 mg co-trimoxazole (oral) will be added to the normal treatment of tuberculosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>co-trimoxazole</intervention_name>
    <description>On 4, 5 or 6 consecutive days, co-trimoxazole 960 mg will be added to the normal treatment regimen</description>
    <arm_group_label>co-trimoxazole</arm_group_label>
    <other_name>Sulfamethoxazole/trimethoprim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  TB Patients with normal susceptible Mycobacterium tuberculosis&#xD;
&#xD;
          -  Patients older than 17 and younger than 64 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Patients with hypersensitivity to sulfonamide or trimethoprim&#xD;
&#xD;
          -  Concomitant treatment with vitamin K antagonists (acenocoumarol)&#xD;
&#xD;
          -  Patients with preexisting renal dysfunction or concomitant treatment of angiotensin&#xD;
             converting enzyme inhibitors and potassium -sparing diuretics) that may exacerbate the&#xD;
             hyperkalemic effect of SXT.&#xD;
&#xD;
          -  Patients treated with methotrexate, phenytoin, sulfonylureas (glibenclamide,&#xD;
             gliclazide, glimepiride en tolbutamide) or procainamide hydrochloride.&#xD;
&#xD;
          -  Patients that have gastrointestinal complaints like diarrhea and vomiting (observed)&#xD;
&#xD;
          -  Patients that have experienced an adverse effect to SXT or similar antibiotic drugs.&#xD;
&#xD;
          -  Patients with HIV or AIDS.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan-Willem C Alffenaar, PharmD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMCG - Tuberculosis Center</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Alsaad N, van Altena R, Pranger AD, van Soolingen D, de Lange WC, van der Werf TS, Kosterink JG, Alffenaar JW. Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis. Eur Respir J. 2013 Aug;42(2):504-12. doi: 10.1183/09031936.00114812. Epub 2012 Oct 25.</citation>
    <PMID>23100498</PMID>
  </reference>
  <reference>
    <citation>Huang TS, Kunin CM, Yan BS, Chen YS, Lee SS, Syu W Jr. Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan. J Antimicrob Chemother. 2012 Mar;67(3):633-7. doi: 10.1093/jac/dkr501. Epub 2011 Nov 29.</citation>
    <PMID>22127584</PMID>
  </reference>
  <reference>
    <citation>Forgacs P, Wengenack NL, Hall L, Zimmerman SK, Silverman ML, Roberts GD. Tuberculosis and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother. 2009 Nov;53(11):4789-93. doi: 10.1128/AAC.01658-08. Epub 2009 Jun 29.</citation>
    <PMID>19564358</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>April 11, 2013</study_first_submitted>
  <study_first_submitted_qc>April 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2013</study_first_posted>
  <last_update_submitted>September 15, 2014</last_update_submitted>
  <last_update_submitted_qc>September 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>JWC Alffenaar</investigator_full_name>
    <investigator_title>PhD PharmD Clinical Pharmacologist</investigator_title>
  </responsible_party>
  <keyword>co-trimoxazole</keyword>
  <keyword>sulfamethoxazole</keyword>
  <keyword>tuberculosis</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

